Shots:
- Fosun Pharma has granted Expedition global rights to develop, manufacture, & commercialize XH-S004, excl. Mainland China, Hong Kong SAR, & Macau SAR, where Fosun will retain its rights
- As per the deal, Fosun will receive $120M incl. upfront & development milestone payments, with ~$525M in sales milestones
- XH-S004 (DPP-1 inhibitor, PO) is being investigated in P-II trials among Chinese pts for non-cystic fibrosis bronchiectasis & P-Ib trials for the treatment of chronic obstructive pulmonary disease
Ref: Fosun Pharma| Image: Fosun Pharma| Press Release
Related News:- Knight Therapeutics and Incyte Expand Latin America Agreement to Include Retifanlimab and Axatilimab
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
